Tadalafil 2.5mg tablets
Requires a prescription from a doctor or prescriber
Drugs for genito-urinary disorders
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Tadalafil
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Tadalafil
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
15 branded products available
Part of the Cialis brand family (generic: Tadalafil)
MHRA licensed products
View all licensed products for Tadalafil on the MHRA register
Cialis 2.5mg tablets
Tadalafil 2.5mg tablets
Tadalafil 2.5mg tablets
Tadalafil 2.5mg tablets
Tadalafil 2.5mg tablets
Tadalafil 2.5mg tablets
Tadalafil 2.5mg tablets
Tadalafil 2.5mg tablets
Tadalafil 2.5mg tablets
Tadalafil 2.5mg tablets
Tadalafil 2.5mg tablets
Tadalafil 2.5mg tablets
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
10 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Tadalafil
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(2)
Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) (TA273)
Erectile dysfunction: avanafil (ESNM45)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
72 found
Half-life
15-17.5h
Mechanism
Tadalafil is a selective phosphodiesterase-5 (PDE5) inhibitor that produces seve…
Food interactions
3 warnings
Human targets
3 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
0.5-6h
[A242270,…
Half-life
15-17.5h
[A242270,…
Protein binding
94%
[A242270][L39095][L39100]
Volume of distribution
63L
[A242270,…
Metabolism
[A242270,…
Elimination
61%
[A242270][L39095][L39100]
These metabolites are mainly excreted in the feces (61%)…
Clearance
2.5-3.4L/h
[A242270,…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L39095][L39439]
It is also indicated for the treatment of pulmonary arterial hypertension (PAH) both alone and in combination with [macitentan] or other endothelin-1 antagonists.
[L39100][L39105][L50622]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1228 interactions
[L39095][L39100]
Standard supportive care is recommended. Hemodialysis is not expected to contribute significantly to tadalafil clearance.
In PAH, blood pressure in the pulmonary arteries is raised due to a variety of mechanisms stemming from endothelial dysfunction.[A242377] Decreased production of NO and prostacyclin reduce vasodilatory signaling while overproduction of endothelin-1 and thromboxane increase vasoconstriction. Inflammation, thromboses, and hypoxia later contribute to vascular remodeling which further reduces luminal size. The resultant increase in blood pressure reduces the capacity for gas exchange and increases afterload at the right ventricle, producing symptoms of dyspnea, fatigue, and dizziness as well as leading to right-sided heart failure. Tadalafil exerts its therapeutic effect in PAH through boosting NO-cGMP signaling to contribute to smooth muscle relaxation as with ED.
Lastly, tadalafil is used to treat BPH.[L39095] BPH produces urinary dysfunction through hyperproliferation of the epithelial and smooth muscle layers of the prostate.[A242382] The increased size of the prostate blocks urine flow through the urethra resulting in higher residual volumes due to incomplete emptying. Tadalafil does not appear to exert its benefit via smooth muscle relaxation of the prostate. It may instead exert its effect through a mix of increased oxygenation and decreased inflammation, which decreases tissue remodeling, and inhibition of cell proliferation through the cGMP cascade.
The decreased affinity for PDE6 compared to other PDE5 inhibitors may explain the decreased incidence of visual side effects as PDE6 is present in the eye and contributes to color vision.[L39100][L39105][A242287]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[A242270][L39095]
The tmax in adults with PAH is reported as 2-8h with a median of 4h.
[L39100]
There does not appear to be a significant effect on absorption when tadalafil is taken with food.
[A242270]
[A242270][L39095][L39100]
The mean half-life of elimination in adults with PAH is reported as 35h.
[L39100]
[A242270][L39095][L39100]
[A242270][L39095]
The mean apparent volume of distribution is reported as 77L in adults with PAH.
[L39100]
[A242270][A242387][L39095][L39100]
This catechol metabolite undergoes subsequent methylation and glucuronidation with the methyl-glucuronide metabolite becoming the primary metabolite in circulation. None of the known metabolites are considered to be active.
[A242270][L39095][L39100]
These metabolites are mainly excreted in the feces (61%) and to a lesser extent in the urine (36%)
[A242270][L39095][L39100]
The mean apparent oral clearance in adults with PAH is reported as 3.5L/h
Proteins and enzymes this drug interacts with in the body
PMID:15489334 PMID:9714779
Specifically regulates nitric-oxide-generated cGMP PMID:15489334
PMID:10725373 PMID:10906126 PMID:11050148 PMID:16330539
Catalyzes the hydrolysis of both cAMP and cGMP to 5'-AMP and 5'-GMP, respectively PMID:10725373 PMID:10906126 PMID:11050148
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC G04BE08
ATC C02KX52
ATC G04CB51
ATC G04CA54
ATC C02KX54
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Tadalafil
Additional database identifiers
Drugs Product Database (DPD)
12346
ChemSpider
99301
BindingDB
14777
PDB
CIA
ZINC
ZINC000003993855
HUGO Gene Nomenclature Committee (HGNC)
HGNC:8784
GenAtlas
PDE5A
GeneCards
PDE5A
GenBank Gene Database
AF043731
GenBank Protein Database
3420185
Guide to Pharmacology
1304
UniProt Accession
PDE5A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:8773
GeneCards
PDE11A
GenBank Gene Database
AB036704
GenBank Protein Database
10716052
Guide to Pharmacology
1311
UniProt Accession
PDE11_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:8789
GeneCards
PDE6G
GenBank Gene Database
M36476
GenBank Protein Database
189703
UniProt Accession
CNRG_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
International reference pricing
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
Patent information
7 active patents, 7 expired
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: